Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?

Impact · against what's priced in

The article presents a bullish case for Pfizer based on dividend sustainability and valuation, but these factors are largely known to the market. While the free cash flow coverage of the dividend is positive, the overarching headwinds of patent cliffs and declining COVID-19 revenues remain the primary drivers of the current low valuation.

PFE+0.10

No priced-in read yet